Spaces:
Running
Running
| { | |
| "spec": "v1.1", | |
| "categories": [ | |
| { | |
| "id": "A", | |
| "name": "ํก์", | |
| "en": "Absorption", | |
| "icon": "๐ซ", | |
| "desc": "๋จน์ ์ฝ์ด ๋ชธ ์์ผ๋ก ๋ค์ด์ค๋๊ฐ", | |
| "planned": 8, | |
| "boards": [ | |
| "Solubility", | |
| "LogP", | |
| "Caco2" | |
| ], | |
| "desc_en": "Whether an orally dosed compound enters the body at all" | |
| }, | |
| { | |
| "id": "D", | |
| "name": "๋ถํฌ", | |
| "en": "Distribution", | |
| "icon": "๐ฉธ", | |
| "desc": "ํ์ก ๋จ๋ฐฑ์ง์ ๋ถ๋๊ฐ ยท ๋๊น์ง ๊ฐ๋๊ฐ", | |
| "planned": 5, | |
| "boards": [ | |
| "PPB", | |
| "Vdss" | |
| ], | |
| "desc_en": "Binding to plasma protein; passage across the blood-brain barrier" | |
| }, | |
| { | |
| "id": "M", | |
| "name": "๋์ฌ", | |
| "en": "Metabolism", | |
| "icon": "๐ฅ", | |
| "desc": "๊ฐ์์ ์ผ๋ง๋ ๋นจ๋ฆฌ ์ฌ๋ผ์ง๋๊ฐ ยท ์ด๋ค ํจ์๊ฐ ๊ฑด๋๋ฆฌ๋๊ฐ", | |
| "planned": 7, | |
| "boards": [ | |
| "CYP3A4", | |
| "CYP2D6", | |
| "CYP2C9" | |
| ], | |
| "desc_en": "How quickly the liver clears it, and which enzymes act on it" | |
| }, | |
| { | |
| "id": "E", | |
| "name": "๋ฐฐ์ค", | |
| "en": "Excretion", | |
| "icon": "๐ง", | |
| "desc": "๋ชธ ๋ฐ์ผ๋ก ์ธ์ ๋๊ฐ๋๊ฐ", | |
| "planned": 2, | |
| "boards": [ | |
| "HalfLife" | |
| ], | |
| "desc_en": "When the compound leaves the body" | |
| }, | |
| { | |
| "id": "T", | |
| "name": "๋ ์ฑ", | |
| "en": "Toxicity", | |
| "icon": "โ ๏ธ", | |
| "desc": "์ฌ์ฅ ยท ๊ฐ ยท ๋ณ์ด์์ฑ. ์ ์ฝ์ด ๊ฐ์ฅ ๋ง์ด ์ฃฝ๋ ์๋ฆฌ", | |
| "planned": 7, | |
| "boards": [ | |
| "hERG", | |
| "LD50" | |
| ], | |
| "desc_en": "Cardiac, hepatic and mutagenic liability โ where candidates most often fail" | |
| }, | |
| { | |
| "id": "P", | |
| "name": "ํจ๋ฅยท์ญ๊ฐ", | |
| "en": "Potency", | |
| "icon": "๐ฏ", | |
| "desc": "ํ์ ์ ์ผ๋ง๋ ์ธ๊ฒ ๋ถ๋๊ฐ", | |
| "planned": 4, | |
| "boards": [ | |
| "AChE", | |
| "MAOB", | |
| "COX2", | |
| "Nav17" | |
| ], | |
| "desc_en": "How tightly a compound binds its intended target" | |
| }, | |
| { | |
| "id": "Z", | |
| "name": "์ํผ์ ๋คํฑ", | |
| "en": "Epigenetics", | |
| "icon": "๐", | |
| "desc": "์ ์ ์๋ฅผ ๋ฐ๊พธ์ง ์๊ณ ์ฝ๋ ๋ฐฉ์์ ๋ฐ๊พผ๋ค", | |
| "desc_en": "Changing how genes are read without changing the genes", | |
| "planned": 5, | |
| "boards": [ | |
| "BRD4", | |
| "HDAC1" | |
| ] | |
| }, | |
| { | |
| "id": "N", | |
| "name": "ํต์์ฉ์ฒด", | |
| "en": "Nuclear receptors", | |
| "icon": "๐งฟ", | |
| "desc": "ํธ๋ฅด๋ชฌ ์ ํธ๋ฅผ ๋ฐ์ ์ ์ ์๋ฅผ ์ผ๊ณ ๋๋ค โ ์ ๋ฐฉ์ยท์ ๋ฆฝ์ ์ ํ์ ", | |
| "desc_en": "Hormone-driven transcription factors โ breast and prostate cancer targets", | |
| "planned": 5, | |
| "boards": [ | |
| "ERalpha", | |
| "AR" | |
| ] | |
| }, | |
| { | |
| "id": "E2", | |
| "name": "ํ๋กํ ์์ ", | |
| "en": "Proteases", | |
| "icon": "โ๏ธ", | |
| "desc": "๋จ๋ฐฑ์ง์ ์๋ฅด๋ ํจ์ โ ์์ธ ํ์ด๋จธยทํญ์๊ณ ยทํญ๋ฐ์ด๋ฌ์ค๊ฐ ์ฌ๊ธฐ ๊ฑธ๋ฆฐ๋ค", | |
| "desc_en": "Protein-cleaving enzymes behind Alzheimer, anticoagulant and antiviral programmes", | |
| "planned": 6, | |
| "boards": [ | |
| "BACE1", | |
| "Thrombin", | |
| "FactorXa" | |
| ] | |
| }, | |
| { | |
| "id": "K", | |
| "name": "ํค๋์์ ยท์ ํ์ฑ", | |
| "en": "Kinase & Selectivity", | |
| "icon": "๐", | |
| "desc": "ํค๋์์ ์๋ฐฑ ๊ฐ ์ค ์ด๋์ ๋ถ๊ณ ์ด๋๋ ํผํ๋๊ฐ", | |
| "planned": 13, | |
| "boards": [ | |
| "EGFR", | |
| "JAK2", | |
| "PI3Ka", | |
| "FLT3", | |
| "VEGFR2", | |
| "CDK2", | |
| "HER2", | |
| "ABL1", | |
| "BRAF", | |
| "KIT", | |
| "ALK", | |
| "Selectivity" | |
| ], | |
| "desc_en": "Which of several hundred kinases are engaged, and which are spared" | |
| }, | |
| { | |
| "id": "R", | |
| "name": "์์ฉ์ฒดยทGPCR", | |
| "en": "Receptors & GPCR", | |
| "icon": "๐ก", | |
| "desc": "์ธํฌ ํ๋ฉด ์์ฉ์ฒด โ ์น์ธ์ฝ ์ธ ๊ฐ ์ค ํ๋๊ฐ ์ฌ๊ธฐ๋ฅผ ๋ ธ๋ฆฐ๋ค", | |
| "desc_en": "Cell-surface receptors โ the target class behind roughly a third of approved drugs", | |
| "planned": 8, | |
| "boards": [ | |
| "D2", | |
| "HT2A", | |
| "MuOpioid", | |
| "KappaOpioid", | |
| "A2A", | |
| "CB1" | |
| ] | |
| }, | |
| { | |
| "id": "S", | |
| "name": "๊ตฌ์กฐ๊ธฐ๋ฐ ๊ฒฐํฉ", | |
| "en": "Structure-based", | |
| "icon": "๐งฌ", | |
| "desc": "์ด๋ค ์์ธ๋ก ๋ถ๋๊ฐ ยท ๊ทธ ์์ธ๊ฐ ๋ฌผ๋ฆฌ์ ์ผ๋ก ๋ง์ด ๋๋๊ฐ", | |
| "planned": 4, | |
| "boards": [], | |
| "desc_en": "The binding pose, and whether that pose is physically admissible" | |
| }, | |
| { | |
| "id": "X", | |
| "name": "์ธํฌยทํํํ", | |
| "en": "Cell & Phenomics", | |
| "icon": "๐ฌ", | |
| "desc": "์ฝ์ด ์ค์ ์ธํฌ์ ๋ฌด์จ ์ง์ ํ๋๊ฐ", | |
| "planned": 5, | |
| "boards": [ | |
| "Phenotype" | |
| ], | |
| "desc_en": "What a compound actually does to a living cell" | |
| }, | |
| { | |
| "id": "I", | |
| "name": "ํญ๊ฐ์ผยท์ ์ธํฌ", | |
| "en": "Anti-infective & whole-cell", | |
| "icon": "๐ฆ ", | |
| "desc": "๊ท ๊ณผ ๊ธฐ์์ถฉ์ด ์ค์ ๋ก ์ฃฝ๋๊ฐ โ ๋จ๋ฐฑ์ง์ด ์๋๋ผ ์๋ฌผ์ ์ฝ๋๋ค", | |
| "desc_en": "Whether the organism actually dies โ the readout is a living cell, not a protein", | |
| "planned": 6, | |
| "boards": [ | |
| "Malaria", | |
| "BSubtilis" | |
| ] | |
| }, | |
| { | |
| "id": "C", | |
| "name": "์์ ์ธ์ค๋ฆฌ์ฝ", | |
| "en": "Clinical in-silico", | |
| "icon": "๐ฅ", | |
| "desc": "์ฌ๋ ๋ชธ์์์ ๋๋ ยท ์ฝ๋ฌผ ์ถฉ๋ ยท ์ฉ๋. ๊ฒจ๋ฃฐ ํ๊ฐ ์์ง ์๋ ์๋ฆฌ", | |
| "planned": 6, | |
| "boards": [ | |
| "Withdrawal" | |
| ], | |
| "desc_en": "Human exposure, drug-drug interaction and dose โ endpoints with no leaderboard yet" | |
| }, | |
| { | |
| "id": "G", | |
| "name": "์์ฑยท๋ชจ๋ฌ๋ฆฌํฐ", | |
| "en": "Generation & Modality", | |
| "icon": "โ๏ธ", | |
| "desc": "์๋ก ๋ง๋ค์ด ๋ด๋ ์ชฝ ยท ์๋ถ์๋ฅผ ๋์ด์๋ ์ชฝ", | |
| "planned": 5, | |
| "boards": [], | |
| "desc_en": "Generating new matter, and modalities beyond small molecules" | |
| } | |
| ] | |
| } |